WO1997041835A1 - Geschmacksverbesserung von arzneimittelwirkstoffen - Google Patents
Geschmacksverbesserung von arzneimittelwirkstoffen Download PDFInfo
- Publication number
- WO1997041835A1 WO1997041835A1 PCT/EP1997/001781 EP9701781W WO9741835A1 WO 1997041835 A1 WO1997041835 A1 WO 1997041835A1 EP 9701781 W EP9701781 W EP 9701781W WO 9741835 A1 WO9741835 A1 WO 9741835A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- taste
- polyol
- active ingredients
- optionally
- dissolving
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Definitions
- the invention relates to a method for improving the taste of solid formulations, such as. b. tablets containing active ingredients or minerals, namely both the actual taste itself and the sensory sensation in the mouth.
- Polyols and polyol mixtures are widely used as non-caries-causing additives and carriers for, among other things, active pharmaceutical ingredients, chewable tablets and lozenges and others
- Polyols are generally obtained by hydrogenating the sugars on which they are based. In solid form, they can be obtained both by crystallization and by spray drying.
- the particular advantage of some polyols lies in the fact that they are also suitable for direct pressing without further auxiliaries and additives.
- the known polyols, mannitol, lactitol, isomalt and xylitol are slightly hygroscopic, but show poor tableting behavior, which is evident in the low tablet hardness, caps and high abrasion of the tablets.
- high tablet hardnesses are sought, since carriers are often only used in small amounts in solid formulations and active ingredients can drastically reduce the tablet hardness, so that a given formulation cannot be tabletted.
- mannitol While lactitol, isomalt and xylitol are rather uncommon in the production of compressed products, mannitol is certainly used in pharmaceutical formulations. However, the use of mannitol represents an increased amount of work, since, as a rule, it has to be wet-granulated with the other constituents of the formulation before it is pressed. Mannit which can be tabletted directly is also available in the trade, but with which it is only possible to achieve unsatisfactory hardnesses compared with those when sorbitol is used. Very good tablet hardnesses are obtained with sorbitol, in particular produced by spray drying. At the same time, the compressed materials produced have particularly smooth surfaces. From a publication by Basedow et. al.
- DC active ingredients are increasingly directly compressible active ingredients
- the invention thus relates to a process for the preparation of DC active ingredients which contribute to improving the taste of solid formulations which contain one or more active ingredients, characterized in that a composition containing one or more active ingredients, obtainable from Co Spray drying or fluidized bed granulation with at least one polyol, by pressing in a solid dosage form.
- the total amount of polyol used is to be chosen so that the powdery substance mixture produced by the process according to the invention contains 10 to 90% by weight, in particular 25 to 75% by weight.
- composition essential to the invention can be obtained by dissolving at least one polyol in water and dissolving or suspending at least one active ingredient in a solvent and spraying the aqueous mixture obtained in an air current with a temperature of 120 to 300 ° C, preferably 140 to 190 ° C.
- a temperature of 120 to 300 ° C preferably 140 to 190 ° C.
- taste-correcting substances and, if appropriate, colorants can be added to the aqueous mixture.
- ausmackskorrigie ⁇ -saving substances are inter alia natural or synthetic sweeteners made from the group of saccharin, aspartame ®, acesulfame K, Neohe- speridin DC, sucralose, thaumatin or stevioside in question.
- Those from the group sorbitol, mannitol, lactitol, isomalt, maltitol, erythritol or xylitol can be used as polyols. These can be contained in the product produced in an amount of 10 to 90% by weight, in particular 25 to 75% by weight.
- the invention thus also relates to the solid formulations produced by the process according to the invention and having an improved taste.
- these formulations on the one hand, minerals from the group of physiologically compatible Ca, Mg, Na, K, Fe and Zn salts in an amount of 0.1 to 90% by weight, in particular 25 to 75% by weight. %, optionally trace elements, and one or more vitamin (s) and optionally one or more possibly bitter-tasting active ingredients.
- the formulations produced by the process according to the invention may contain one or more active pharmaceutical ingredients.
- active ingredients can include antacids, antiallergics, analgesics, hormones, steroids, estrogens, contraceptives, nasal decongestants, hi and hr antagonists, ß 2 stimulants, vasodilators, antihypertensives, infection-preventing agents, laxatives, antioxidants, antitussive drugs Sore throat, bismuth and its salts, fungal agents, antibiotics, stimulants (such as, for example, amphetamines) alkaloids, oral hypoglycaemics, diuretics, cholesterol-lowering agents, combinations of various pharmaceutically active agents or others.
- These active substances can be contained in an amount of 0.1 to 70% by weight.
- the active substances can be present as coated particles, liposomes or microparticles. Common substances used in pharmacy can serve as the coating.
- the particle size of the active ingredients is preferably 0.1 to 800 ⁇ m with a bulk density of 0.15 to 1 g / cm 3 .
- polyol stands for sugar alcohols of the general formula
- n 2 to 6, preferably 3 to 4, and their dimeric anhydrides, in particular C12H24O11.
- polyols stands for hexites such as sorbitol and
- Mannitol pentites such as xylitol, but also possible are C 4 polyalcohols such as erythritol or Ci 2 polyalcohols such as lactitol or maltitol.
- C 4 polyalcohols such as erythritol or Ci 2 polyalcohols
- lactitol or maltitol are C 4 polyalcohols
- polyols also stands for suitable carbohydrates.
- An aqueous solution of at least one polyol is used for spray drying.
- the solids content is preferably increased beforehand by mixing at a temperature of up to 80 ° C. of at least one polyol solution with one or more solutions or suspensions of the desired active ingredient (s) in the desired ratio to about 10 to 90% by weight, in particular 50 to 72% by weight.
- the spraying is carried out by atomization by means of nozzles, preferably by means of a centrifugal atomizer, in a dry, centrifugally blown air stream heated to a temperature of 120 to 300 ° C., preferably 140 to 190 ° C.
- the amount of the polyol solution fed in and the hot air blown in are adjusted so that the powdery substance mixture obtained is dried to a water content of about 0.1 to about 1% by weight, if appropriate in a fluidized bed. In any case, the water content should be below 1% by weight.
- the fluidized bed granulation is such. B. in P. Grassmann, F. Widmer "Introduction to thermal process engineering" described.
- binders to be added are familiar to the person skilled in the art and serve to increase the strength of the composition.
- Preferred binders are cellulose derivatives, in particular hydroxypropyl methyl cellulose, carboxymethyl cellulose or starch.
- composition of the tablet material is composition of the tablet material:
- ASA Acetylsalicylic acid
- ASS is finely powdered by grinding and triturated with Sorbit Instant in a turbulent shaker mixer including the micronized sweetener ASK. This is followed by screening for deagglomeration using a 1 mm sieve and subsequent mixing with magnesium stearate and then tableting.
- Finely powdered, ground ASS is partly (about 5%) placed in the fluidized bed, and the rest is dispersed in a ratio of about 1: 1 in Sor ⁇ bit solution.
- the dispersion is maintained by stirring and sprayed directly into the fluidized bed with the sweetener ASK, with simultaneous water evaporation.
- the relatively fine spray granulate thus formed is admixed with 1% magnesium stearate as a lubricant.
- the mixture obtained is tabletted directly.
- Ascorbic acid, sorbitol and sweetener are dissolved with approx. 40% solids in water at 40 ° C and sprayed onto an equally composed bed of crystal nuclei (approx. 15% of the total mass) in the vortex device.
- the spray granulate is mixed with the same flavor and magnesium stearate before tabletting.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU9903613A HUP9903613A3 (en) | 1996-05-02 | 1997-04-10 | Improvement in the taste of active pharmaceutical ingredients |
JP9539463A JP2000509400A (ja) | 1996-05-02 | 1997-04-10 | 医薬の香味改善 |
AT97917302T ATE243025T1 (de) | 1996-05-02 | 1997-04-10 | Geschmacksverbesserung von arzneimittelwirkstoffen |
CZ0348698A CZ296178B6 (cs) | 1996-05-02 | 1997-04-10 | Zpusob zlepsení chuti farmaceutických cinidel |
ES97917302T ES2202601T5 (es) | 1996-05-02 | 1997-04-10 | Mejora del sabor de sustancias activas de medicamentos |
DE59710309T DE59710309D1 (de) | 1996-05-02 | 1997-04-10 | Geschmacksverbesserung von arzneimittelwirkstoffen |
EP97917302.8A EP0904059B2 (de) | 1996-05-02 | 1997-04-10 | Geschmacksverbesserung von arzneimittelwirkstoffen |
US09/180,022 US6149941A (en) | 1996-05-02 | 1997-04-10 | Taste of active pharmaceutical ingredients |
CA002253386A CA2253386A1 (en) | 1996-05-02 | 1997-04-10 | Improvement in the taste of active pharmaceutical ingredients |
DK97917302T DK0904059T3 (da) | 1996-05-02 | 1997-04-10 | Forbedring af smagen af lægemiddelaktivstoffer |
HK99104345A HK1019141A1 (en) | 1996-05-02 | 1999-10-06 | Flavour improvement of pharmaceutical agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19617487A DE19617487A1 (de) | 1996-05-02 | 1996-05-02 | Geschmacksverbesserung von Arzneimittelwirkstoffen |
DE19617487.2 | 1996-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997041835A1 true WO1997041835A1 (de) | 1997-11-13 |
Family
ID=7793025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/001781 WO1997041835A1 (de) | 1996-05-02 | 1997-04-10 | Geschmacksverbesserung von arzneimittelwirkstoffen |
Country Status (16)
Country | Link |
---|---|
US (1) | US6149941A (de) |
EP (1) | EP0904059B2 (de) |
JP (1) | JP2000509400A (de) |
CN (1) | CN1143673C (de) |
AT (1) | ATE243025T1 (de) |
CA (1) | CA2253386A1 (de) |
CZ (1) | CZ296178B6 (de) |
DE (2) | DE19617487A1 (de) |
DK (1) | DK0904059T3 (de) |
ES (1) | ES2202601T5 (de) |
HK (1) | HK1019141A1 (de) |
HU (1) | HUP9903613A3 (de) |
ID (1) | ID18516A (de) |
MY (1) | MY116896A (de) |
RU (1) | RU2180560C2 (de) |
WO (1) | WO1997041835A1 (de) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2778822A1 (fr) * | 1998-05-25 | 1999-11-26 | Roquette Freres | Composition edulcorante et ses utilisations |
JP2000086537A (ja) * | 1998-09-11 | 2000-03-28 | Fuji Chem Ind Co Ltd | 無機化合物糖類組成物、賦形剤、速崩壊性圧縮成型物及びその製造方法 |
JP2001342151A (ja) * | 2000-03-31 | 2001-12-11 | Eisai Co Ltd | 甘味を有する薬剤組成物 |
WO2004086885A1 (en) * | 2003-03-31 | 2004-10-14 | Mcneil- Ppc, Inc. | High intensity sweetner composition and delivery of same |
WO2004112506A1 (en) * | 2003-06-16 | 2004-12-29 | Tate & Lyle Public Limited Company | Granulated sucralose product |
WO2005087020A1 (en) * | 2004-03-05 | 2005-09-22 | Richmond Chemical Corporation | High-intensity sweetener-polyol compositions |
US7118765B2 (en) | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
US7750146B2 (en) | 2005-03-18 | 2010-07-06 | Tate & Lyle Plc | Granular sucralose |
US8632798B2 (en) | 2001-12-11 | 2014-01-21 | Ceapro Inc. | Cereal β glucan compositions, methods of preparation and uses thereof |
US8642081B2 (en) | 2004-06-01 | 2014-02-04 | Takeda Nycomed As | Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance |
US8808735B2 (en) | 2005-02-03 | 2014-08-19 | Takeda Nycomed As | Fast wet-massing method for the preparation of calcium-containing compositions |
US8846088B2 (en) | 2005-02-03 | 2014-09-30 | Takeda Nycomed As | Melt granulation of a composition containing a calcium-containing compound |
US8846101B2 (en) | 2005-12-07 | 2014-09-30 | Takeda Nycomed As | Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions |
US8906411B2 (en) | 2005-12-07 | 2014-12-09 | Takeda Nycomed As | Pre-compacted calcium-containing compositions |
US9101565B2 (en) | 2008-11-17 | 2015-08-11 | Takeda Nycomed As | Dissolution stability of calcium carbonate tablets |
US10258576B2 (en) | 2004-05-24 | 2019-04-16 | Takeda As | Particulate comprising a calcium-containing compound and a sugar alcohol |
US11166917B2 (en) | 2008-06-20 | 2021-11-09 | Merck Patent Gmbh | Direct injection moldable and rapidly disintegrating tablet matrix |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US6057139A (en) | 1995-06-29 | 2000-05-02 | Mcneil-Ppc, Inc. | Preblend of microcrystalline cellulose and lactase for making tablets |
US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
US6599534B2 (en) | 1997-12-03 | 2003-07-29 | Pancosma Societe Anonyme Pour L'industrie Des Produits | Masking agent in powder form for pharmaceutical tastes |
EP0920861A1 (de) * | 1997-12-03 | 1999-06-09 | Laboratoires Pancosma S.A. | Geschmacksmaskierende Pulver für Pharmazeutika |
GB9825033D0 (en) * | 1998-11-13 | 1999-01-13 | Nycomed Pharma As | Process |
DE10031044A1 (de) * | 2000-06-26 | 2002-01-03 | Bayer Ag | Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere |
US7575761B2 (en) * | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
WO2002009669A2 (en) * | 2000-08-01 | 2002-02-07 | Inhale Therapeutic Systems, Inc. | Apparatus and process to produce particles having a narrow size distribution and particles made thereby |
JP2002060339A (ja) * | 2000-08-17 | 2002-02-26 | Takeda Chem Ind Ltd | 高甘味度甘味料含有組成物およびその利用 |
GB0027357D0 (en) * | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
NZ530511A (en) * | 2001-07-16 | 2005-06-24 | Astrazeneca Ab | A tablet for treating disorders of the gastrointestinal tract comprising a proton pump inhibitor and at least one antacid that has a barrier layer to cover an enteric coating film |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
AU2002342241B2 (en) * | 2001-11-01 | 2007-07-19 | Novartis Ag | Spray drying methods and compositions thereof |
AU2002361596A1 (en) * | 2001-11-07 | 2003-05-19 | Pharmacia Corporation | Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process |
GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
FI20021312A (fi) * | 2002-07-03 | 2004-01-04 | Danisco Sweeteners Oy | Polyolikoostumusten kiteyttäminen, kiteinen polyolikoostumustuote ja sen käyttö |
JP4526247B2 (ja) * | 2002-07-08 | 2010-08-18 | 第一三共株式会社 | 経口用セファロスポリン製剤 |
DE10240778A1 (de) * | 2002-08-30 | 2004-03-11 | Merck Patent Gmbh | Verfahren zur Herstellung von direkt tablettierbarem a-Mannit |
EP1545521A2 (de) * | 2002-10-04 | 2005-06-29 | Pharmacia Corporation | Zusammensetzungen und verfahren zur behandlung der sexuellen dysfunktion |
MXPA05007154A (es) | 2002-12-30 | 2005-09-21 | Nektar Therapeutics | Atomizador prepeliculizacion. |
US7862834B2 (en) * | 2003-05-28 | 2011-01-04 | Novartis Pharma Ag | Pharmaceutical formulation comprising a water-insoluble active agent |
US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
NZ555501A (en) | 2004-11-24 | 2010-01-29 | Medpointe Healthcare Inc | Compositions comprising azelastine and methods of use thereof |
ES2324957T5 (es) * | 2005-03-04 | 2012-08-21 | Nycomed Pharma As | Proceso para la producción de composiciones de calcio en un lecho fluido continuo |
US20070116836A1 (en) * | 2005-11-23 | 2007-05-24 | The Coca-Cola Company | High-Potency Sweetener Composition for Treatment and/or Prevention of Osteoporosis and Compositions Sweetened Therewith |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
ES2538082T3 (es) | 2007-02-11 | 2015-06-17 | Map Pharmaceuticals Inc | Método de administración terapéutica de DHE para permitir el rápido alivio de migraña mientras que se minimiza el perfil de efectos secundarios |
WO2008109018A1 (en) * | 2007-03-02 | 2008-09-12 | Meda Pharmaceuticals Inc. | Compositions comprising carisoprodol and methods of use thereof |
FR2925499B1 (fr) * | 2007-12-20 | 2010-02-12 | Roquette Freres | Maltitol granule pour compression directe et son procede de preparation |
ES2720626T3 (es) * | 2008-06-20 | 2019-07-23 | Merck Patent Gmbh | Combinación de poliol compresible directamente |
CN102112114A (zh) * | 2008-08-08 | 2011-06-29 | 麦克内尔-Ppc股份有限公司 | 使用三氯蔗糖作为制粒剂 |
CA2753685C (en) | 2009-03-09 | 2017-09-12 | Spi Pharma, Inc. | Highly compactable and durable direct compression excipients and excipient systems |
CA2755543A1 (en) * | 2009-03-13 | 2010-09-16 | Nucitec S.A. De C.V. | Compositions and methods for treatment and prevention of cardiovascular disease |
US9808030B2 (en) | 2011-02-11 | 2017-11-07 | Grain Processing Corporation | Salt composition |
US10369108B2 (en) | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
EP3061501A1 (de) | 2015-02-27 | 2016-08-31 | Rottapharm Ltd. | Zusammensetzung zur behandlung von akne |
EP3117825A1 (de) | 2015-07-16 | 2017-01-18 | Rottapharm S.p.A. | Orale formulierung mit berberin und morus-alba-extrakt |
JP6955517B2 (ja) * | 2016-05-13 | 2021-10-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 可塑剤として直接圧縮可能な賦形剤を使用する加熱溶融押出組成物 |
RU2634373C1 (ru) * | 2016-06-29 | 2017-10-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ повышения уровня работоспособности у лабораторных животных в эксперименте |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4610878B1 (de) | 1969-08-05 | 1971-03-19 | ||
JPS5512889A (en) | 1978-06-05 | 1980-01-29 | Snia Viscosa | Spinning finish composition of highly crimped viscose fiber |
EP0143576A1 (de) * | 1983-11-18 | 1985-06-05 | Warner-Lambert Canada Inc. | Eine antacide Zusammensetzung und ein Verfahren zu ihrer Herstellung |
JPS63205136A (ja) | 1987-02-18 | 1988-08-24 | Fuji Sangyo Kk | 粉体処理装置 |
JPS6467249A (en) | 1987-09-07 | 1989-03-13 | Fuji Sangyo Co Ltd | Powder treatment device |
US4892889A (en) * | 1986-11-18 | 1990-01-09 | Basf Corporation | Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin |
JPH02300135A (ja) | 1989-05-11 | 1990-12-12 | Kanebo Ltd | 漢方エキス粉末造粒物の製造方法 |
JPH035848A (ja) | 1989-05-15 | 1991-01-11 | Internatl Business Mach Corp <Ibm> | 分散データ処理システムにおけるフアイル属性の管理方式 |
JPH0595988A (ja) | 1990-10-22 | 1993-04-20 | Kanebo Ltd | 漢方エキス造粒物および漢方エキス含有固形製剤の製造方法 |
JPH05255080A (ja) * | 1992-03-13 | 1993-10-05 | Taisho Pharmaceut Co Ltd | 塩酸ミドドリン含有製剤 |
JPH06219134A (ja) | 1993-01-26 | 1994-08-09 | Mazda Motor Corp | 車両のレイアウト構造 |
JPH06219135A (ja) | 1993-01-28 | 1994-08-09 | Nissan Motor Co Ltd | 車両用冷暖房装置 |
JPH06329980A (ja) | 1993-05-19 | 1994-11-29 | Toagosei Chem Ind Co Ltd | 金属被覆用樹脂組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272704A (en) † | 1963-06-06 | 1966-09-13 | Armour Pharma | Stable aluminum hydroxide-magnesium compound codried gel antacids and process of making the same |
US4446135A (en) † | 1982-06-07 | 1984-05-01 | Sterling Drug Inc. | Chewable antacid tablets |
US4676984A (en) † | 1985-08-14 | 1987-06-30 | American Home Products Corp. | Rehydratable antacid composition |
IE873172L (en) † | 1986-12-29 | 1988-06-29 | Harvard College | Continuous process for producing a comestible tablet |
US5075291A (en) † | 1989-11-22 | 1991-12-24 | Ici Americas Inc. | Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound |
DE4128260C2 (de) † | 1991-08-26 | 1995-09-14 | Milupa Ag | Verfahren zur Herstellung eines phenylalaninfreien Diätetikums in Dragee- oder Tablettenform |
JP3265680B2 (ja) † | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
FR2710637B1 (fr) † | 1993-09-28 | 1995-12-08 | Roquette Freres | Mannitol pulvérulent de friabilité modérée et son procédé de préparation. |
DK0834314T3 (da) † | 1995-06-12 | 2003-02-24 | Ono Pharmaceutical Co | Granuler der indeholder pranlukast, fremgangsmåde til fremstilling af granulerne, og fremgangsmåde til reduktion af pranlukasts klæbeevne |
-
1996
- 1996-05-02 DE DE19617487A patent/DE19617487A1/de not_active Withdrawn
-
1997
- 1997-04-10 US US09/180,022 patent/US6149941A/en not_active Expired - Lifetime
- 1997-04-10 EP EP97917302.8A patent/EP0904059B2/de not_active Expired - Lifetime
- 1997-04-10 AT AT97917302T patent/ATE243025T1/de active
- 1997-04-10 HU HU9903613A patent/HUP9903613A3/hu unknown
- 1997-04-10 DK DK97917302T patent/DK0904059T3/da active
- 1997-04-10 CN CNB971942773A patent/CN1143673C/zh not_active Expired - Fee Related
- 1997-04-10 CZ CZ0348698A patent/CZ296178B6/cs not_active IP Right Cessation
- 1997-04-10 WO PCT/EP1997/001781 patent/WO1997041835A1/de active IP Right Grant
- 1997-04-10 ES ES97917302T patent/ES2202601T5/es not_active Expired - Lifetime
- 1997-04-10 RU RU98121702/14A patent/RU2180560C2/ru not_active IP Right Cessation
- 1997-04-10 CA CA002253386A patent/CA2253386A1/en not_active Abandoned
- 1997-04-10 JP JP9539463A patent/JP2000509400A/ja active Pending
- 1997-04-10 DE DE59710309T patent/DE59710309D1/de not_active Expired - Lifetime
- 1997-04-24 MY MYPI97001792A patent/MY116896A/en unknown
- 1997-05-01 ID IDP971460A patent/ID18516A/id unknown
-
1999
- 1999-10-06 HK HK99104345A patent/HK1019141A1/xx not_active IP Right Cessation
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4610878B1 (de) | 1969-08-05 | 1971-03-19 | ||
JPS5512889A (en) | 1978-06-05 | 1980-01-29 | Snia Viscosa | Spinning finish composition of highly crimped viscose fiber |
EP0143576A1 (de) * | 1983-11-18 | 1985-06-05 | Warner-Lambert Canada Inc. | Eine antacide Zusammensetzung und ein Verfahren zu ihrer Herstellung |
US4892889A (en) * | 1986-11-18 | 1990-01-09 | Basf Corporation | Process for making a spray-dried, directly-compressible vitamin powder comprising unhydrolyzed gelatin |
JPS63205136A (ja) | 1987-02-18 | 1988-08-24 | Fuji Sangyo Kk | 粉体処理装置 |
JPS6467249A (en) | 1987-09-07 | 1989-03-13 | Fuji Sangyo Co Ltd | Powder treatment device |
JPH02300135A (ja) | 1989-05-11 | 1990-12-12 | Kanebo Ltd | 漢方エキス粉末造粒物の製造方法 |
JPH035848A (ja) | 1989-05-15 | 1991-01-11 | Internatl Business Mach Corp <Ibm> | 分散データ処理システムにおけるフアイル属性の管理方式 |
JPH0595988A (ja) | 1990-10-22 | 1993-04-20 | Kanebo Ltd | 漢方エキス造粒物および漢方エキス含有固形製剤の製造方法 |
JPH05255080A (ja) * | 1992-03-13 | 1993-10-05 | Taisho Pharmaceut Co Ltd | 塩酸ミドドリン含有製剤 |
JPH06219134A (ja) | 1993-01-26 | 1994-08-09 | Mazda Motor Corp | 車両のレイアウト構造 |
JPH06219135A (ja) | 1993-01-28 | 1994-08-09 | Nissan Motor Co Ltd | 車両用冷暖房装置 |
JPH06329980A (ja) | 1993-05-19 | 1994-11-29 | Toagosei Chem Ind Co Ltd | 金属被覆用樹脂組成物 |
Non-Patent Citations (3)
Title |
---|
DATABASE WPI Section Ch Week 9344, Derwent World Patents Index; Class B05, AN 93-348346, XP002042144 * |
ISHIHARA ET AL., PHARMATECH JAPAN, vol. 8, 1992, pages 75 - 80 |
SUNADA ET AL., 27TH TECHNICAL SYMPOSIUM ON GRANULATION AND ITS APPLIED TECHNOLOGY, 30 June 1992 (1992-06-30) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2778822A1 (fr) * | 1998-05-25 | 1999-11-26 | Roquette Freres | Composition edulcorante et ses utilisations |
JP2000086537A (ja) * | 1998-09-11 | 2000-03-28 | Fuji Chem Ind Co Ltd | 無機化合物糖類組成物、賦形剤、速崩壊性圧縮成型物及びその製造方法 |
JP2001342151A (ja) * | 2000-03-31 | 2001-12-11 | Eisai Co Ltd | 甘味を有する薬剤組成物 |
US8632798B2 (en) | 2001-12-11 | 2014-01-21 | Ceapro Inc. | Cereal β glucan compositions, methods of preparation and uses thereof |
US8545889B2 (en) | 2001-12-17 | 2013-10-01 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
US10702605B2 (en) | 2001-12-17 | 2020-07-07 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
US9138413B2 (en) | 2001-12-17 | 2015-09-22 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
US7118765B2 (en) | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
US6984732B2 (en) | 2003-03-31 | 2006-01-10 | Mcneil-Ppc, Inc. | High-intensity sweetener composition and delivery of same |
WO2004086885A1 (en) * | 2003-03-31 | 2004-10-14 | Mcneil- Ppc, Inc. | High intensity sweetner composition and delivery of same |
WO2004112506A1 (en) * | 2003-06-16 | 2004-12-29 | Tate & Lyle Public Limited Company | Granulated sucralose product |
WO2005087020A1 (en) * | 2004-03-05 | 2005-09-22 | Richmond Chemical Corporation | High-intensity sweetener-polyol compositions |
US10357460B2 (en) | 2004-05-24 | 2019-07-23 | Takeda As | Particulate comprising a calcium-containing compound and a sugar alcohol |
US10258576B2 (en) | 2004-05-24 | 2019-04-16 | Takeda As | Particulate comprising a calcium-containing compound and a sugar alcohol |
US8642081B2 (en) | 2004-06-01 | 2014-02-04 | Takeda Nycomed As | Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance |
US8808735B2 (en) | 2005-02-03 | 2014-08-19 | Takeda Nycomed As | Fast wet-massing method for the preparation of calcium-containing compositions |
US8846088B2 (en) | 2005-02-03 | 2014-09-30 | Takeda Nycomed As | Melt granulation of a composition containing a calcium-containing compound |
US8101746B2 (en) | 2005-03-18 | 2012-01-24 | Tate & Lyle Technology Limited | Granular sucralose, and method of making it |
US7750146B2 (en) | 2005-03-18 | 2010-07-06 | Tate & Lyle Plc | Granular sucralose |
US8906411B2 (en) | 2005-12-07 | 2014-12-09 | Takeda Nycomed As | Pre-compacted calcium-containing compositions |
US8846101B2 (en) | 2005-12-07 | 2014-09-30 | Takeda Nycomed As | Film-coated and/or granulated calcium-containing compounds and use thereof in pharmaceutical compositions |
US9801907B2 (en) | 2005-12-07 | 2017-10-31 | Takeda As | Film-coated and/or granulated calcium-containing compounds and use therof in pharmaceutical compositions |
US11166917B2 (en) | 2008-06-20 | 2021-11-09 | Merck Patent Gmbh | Direct injection moldable and rapidly disintegrating tablet matrix |
US9101565B2 (en) | 2008-11-17 | 2015-08-11 | Takeda Nycomed As | Dissolution stability of calcium carbonate tablets |
US9999634B2 (en) | 2008-11-17 | 2018-06-19 | Takeda As | Dissolution stability of calcium carbonate tablets |
Also Published As
Publication number | Publication date |
---|---|
CN1216919A (zh) | 1999-05-19 |
HUP9903613A2 (hu) | 2000-03-28 |
DK0904059T3 (da) | 2003-10-06 |
MY116896A (en) | 2004-04-30 |
DE59710309D1 (de) | 2003-07-24 |
CZ296178B6 (cs) | 2006-01-11 |
DE19617487A1 (de) | 1997-11-06 |
EP0904059B2 (de) | 2013-06-19 |
CN1143673C (zh) | 2004-03-31 |
US6149941A (en) | 2000-11-21 |
HK1019141A1 (en) | 2000-01-14 |
JP2000509400A (ja) | 2000-07-25 |
ES2202601T5 (es) | 2013-09-26 |
ID18516A (id) | 1998-04-16 |
EP0904059B1 (de) | 2003-06-18 |
ES2202601T3 (es) | 2004-04-01 |
HUP9903613A3 (en) | 2000-04-28 |
EP0904059A1 (de) | 1999-03-31 |
CA2253386A1 (en) | 1997-11-13 |
RU2180560C2 (ru) | 2002-03-20 |
ATE243025T1 (de) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0904059B1 (de) | Geschmacksverbesserung von arzneimittelwirkstoffen | |
DE69933689T2 (de) | Verfahren zur herstellung von oralen calcium zusammensetzungen | |
DE2058434C3 (de) | Verfahren zum Herstellen von freifließenden, leicht benetzbaren Acetylsalicylsäure enthaltenden Arzneünittelteilchen zur Bereitstellung von brausenden Zubereitungen | |
DE3685927T2 (de) | Vitamine enthaltende granule. | |
DE69025150T2 (de) | Pharmazeutische Lutschpastillen | |
DE69925016T2 (de) | Verbesserte tablette mit schneller auflösbarkeit | |
DE68903605T2 (de) | Kautablette. | |
DE69233130T2 (de) | Kaubare zusammensetzung zur arzneimittelfreisetzung | |
DE68916731T2 (de) | Morphin enthaltende Zusammensetzung. | |
DE60202794T2 (de) | Orodispersible tablette mit hoher homogenität und herstellungsverfahren dafür | |
DE19615418A1 (de) | Polyol-Zusammensetzung | |
DE4140689A1 (de) | Inhalationspulver und verfahren zu ihrer herstellung | |
DE69718046T3 (de) | Direkt verpressbares lactitol und verfahren dazu | |
EP0481294A1 (de) | Feste, schnell-lösliche Arzneimittelzubereitung enthaltend S-(Carboxymethyl)-L-Cystein und/oder N-Acetylcystein | |
EP1213974B1 (de) | Direkt verpressbarer rohstoff für komprimate | |
EP2299982B1 (de) | Direkt verpressbare und schnell zerfallende tablettenmatirx | |
EP1023049B1 (de) | Herstellung eines direkt verpressbaren tablettierhilfsstoffes | |
DE69012932T2 (de) | Zubereitung für schäumendes Präparat. | |
EP2293774B1 (de) | Direkt verpressbare polyolkombination | |
WO1999006029A1 (de) | Formulierung auf der basis von ascorbinsäure mit verbesserter farbstabilität | |
EP0922450A1 (de) | Brausezubereitung enthaltend ein Pflanzenextrakt | |
DD236453A5 (de) | Verfahren zur herstellung von nifedinpraeparaten | |
DE29521515U1 (de) | Eine therapeutische Kombination aus Vitamin und Calcium in einheitlicher galenischer Tablettenform | |
EP1589944B1 (de) | Pharmazeutische zubereitungen und verfahren zu deren herstellung | |
KR100466897B1 (ko) | 약제학적활성성분의향미개선 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97194277.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN CZ HU JP KR LT LV RU SG SI US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1997917302 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2253386 Country of ref document: CA Ref document number: 2253386 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1998-3486 Country of ref document: CZ Ref document number: 09180022 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019980708810 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV1998-3486 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1997917302 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019980708810 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997917302 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019980708810 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1998-3486 Country of ref document: CZ |